Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
122.8 USD | -0.79% | -3.75% | -15.01% |
May. 30 | Chile's ENAMI aims to break ground on first lithium project by 2028 | RE |
May. 21 | Scotiabank Downgrades Albemarle to Sector Perform From Sector Outperform, Price Target is $135 | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The group shows a rather high level of debt in proportion to its EBITDA.
- With a 2024 P/E ratio at 43.4 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.01% | 14.41B | C+ | ||
+17.07% | 66.31B | A- | ||
-0.29% | 48.46B | A- | ||
+21.61% | 43.27B | B+ | ||
+26.72% | 27.41B | A- | ||
+9.25% | 19.26B | C+ | ||
+9.75% | 16.58B | B+ | ||
-2.14% | 16.61B | B+ | ||
-30.22% | 14.02B | A- | ||
-22.45% | 13.34B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALB Stock
- Ratings Albemarle Corporation